New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . READ ARTICLE PUBLISHED MARCH 23, 2021
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S.